In yesterday’s Wall Street session, ProKidney Corp. (NASDAQ:PROK) shares traded at $12.66, down -2.24% from the previous session.
As of this writing, 2 analysts cover ProKidney Corp. (NASDAQ:PROK). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $18.00 and a low of $15.00, we find $16.50. Given the previous closing price of $12.95, this indicates a potential upside of 27.41 percent. PROK stock price is now 22.75% away from the 50-day moving average and 32.89% away from the 200-day moving average. The market capitalization of the company currently stands at $2.98B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $16.50 as their price target over the next twelve months.
With the price target of $15, Jefferies recently initiated with Buy rating for ProKidney Corp. (NASDAQ: PROK). On November 10, 2022, Morgan Stanley recently initiated its ‘Equal-Weight’ rating on the stock quoting a target price of $13, while ‘UBS’ rates the stock as ‘Buy’.
In other news, Cowen Aaron, 10% Owner bought 7,007 shares of the company’s stock on Sep 06. The stock was bought for $48,979 at an average price of $6.99. Upon completion of the transaction, the 10% Owner now directly owns 6,280,175 shares in the company, valued at $79.51 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 31, 10% Owner Cowen Aaron bought 3,162 shares of the business’s stock. A total of $28,258 was incurred on buying the stock at an average price of $8.94. This leaves the insider owning 6,273,168 shares of the company worth $79.42 million. Insiders disposed of 9,947,000 shares of company stock worth roughly $125.93 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PROK stock. A new stake in ProKidney Corp. shares was purchased by SOCIAL CAPITAL GROUP LLC during the first quarter worth $168,036,000. BROWN UNIVERSITY invested $12,660,000 in shares of PROK during the first quarter. In the first quarter, SWISS NATIONAL BANK acquired a new stake in ProKidney Corp. valued at approximately $941,000. STATE STREET CORP acquired a new stake in PROK for approximately $647,000. EXOS ASSET MANAGEMENT LLC purchased a new stake in PROK valued at around $534,000 in the second quarter. In total, there are 31 active investors with 35.80% ownership of the company’s stock.
Wednesday morning saw ProKidney Corp. (NASDAQ: PROK) opened at $12.87. During the past 12 months, ProKidney Corp. has had a low of $5.14 and a high of $14.19. The fifty day moving average price for PROK is $10.43 and a two-hundred day moving average price translates $9.54 for the stock.
The latest earnings results from ProKidney Corp. (NASDAQ: PROK) was released for Sep, 2022. The company reported revenue of $35.57 million for the quarter, compared to $17.08 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 108.25 percent.
ProKidney Corp.(PROK) Company Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
